PYC Therapeutics Limited (PYC) Earnings Call Transcripts

PYC Therapeutics Limited's Latest Earnings Call - May 22, 2026

In the second quarter of fiscal year 2026, PYC Therapeutics Limited reported significant progress in its clinical development pipeline, particularly in polycystic kidney disease (PKD) and Phelan-McDermid Syndrome (PMS). The management emphasized that they are 'very proximate to the evaluation of the safety, but importantly, the early efficacy signs in 3 of those 4 programs.' Revenue figures were not disclosed, but the focus on execution and upcoming data readouts could drive stock movement. Management maintained its operational roadmap, signaling a strong commitment to advancing clinical trials and addressing unmet patient needs.

Reported metrics

Guidance from management

Management is focused on executing their operational roadmap and expects significant data readouts in the next 24 months, particularly in PKD and PMS, which could drive future growth.

What management said

Earlier, you mentioned that 3 of the 4 programs are large markets. I read various sources that both the PMS and PKD markets are actually materially larger than you have on your slides. Are you being intentionally conservative or am I reading poor research?

Yes, I think we're very much on track with the operational road map that we set out at the beginning of the session. So the idea there, as I touched on during the PMS program, deep dive is to initiate clinical development in the second half of this year in the context of the natural history studies and then to transition through an IND to first patient in an interventional study in the first half of next year.

What analysts pressed on

Analysts expressed concerns regarding the clarity of regulatory requirements for the ophthalmology programs, particularly the high bar for visual acuity improvements needed for approval. There is also apprehension about the timeline for data readouts and their impact on stock valuation.

Main topics on the call

• Clinical Development Progress — PYC is on track with its clinical development, particularly for PKD and PMS. Management stated, 'the focus of the organization now is very much on execution,' indicating a strong commitment to meeting upcoming milestones...
• Market Potential for Drug Candidates — Management acknowledged the potential for larger market sizes than previously estimated for both PKD and PMS, stating, 'we do think that Phelan-McDermid Syndrome is a very, very large market.' This suggests a bullish out...
• Safety Profile of Drug Candidates — The management highlighted a clean safety profile, noting, 'we have not had a treatment-related serious adverse event in any subject, in any clinical trial.' This is crucial for investor confidence as they approach late-...
• Guidance on Upcoming Data Readouts — Management indicated that key data readouts are expected in the next 24 months, stating, 'the data that is coming now is really the data that matters.' This sets the stage for potential stock catalysts.

Read the full PYC Therapeutics Limited transcript (May 22, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 29 PYC Therapeutics Limited earnings call transcripts on record, spanning August 17, 2021 to July 15, 2026. Based on this history, PYC Therapeutics Limited reports quarterly. The most recent call on file is dated July 15, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

PYC

Exchange

ASX

Country

AU

Sector

Health Care

Industry

Biotechnology

Calls on record

29

First call

August 17, 2021

Most recent

July 15, 2026

Reporting cadence

quarterly